Keeping up with the FDA and their rules for peptides is a bit like trying to read a map that someone is actively redrawing. Between safety alerts and new categories, there is a lot to track.
The big shift for Semaglutide
For a while, Semaglutide was under a national shortage, which changed how pharmacies could make it. As of September 2026, the national shortage-related compounding period has ended.
- Status Update: The FDA has proposed excluding Semaglutide from the 503B Bulks List (a list of ingredients that outsourcing facilities can use) because they do not see a clinical need for it.
- Warning Labels: FDA alerts have been issued regarding dosing errors and the use of salt forms like semaglutide sodium or acetate, which are not the same as the active ingredients in approved drugs.
- Real Results: In the STEP 1 trial, this compound showed a 14.9% weight loss, and the SELECT trial showed a 20% reduction in major cardiovascular events.
Safety signals you should know about
When thousands of people use a compound, new safety signals start to pop up. A safety signal is just a fancy way of saying "we noticed a pattern of side effects that we need to watch."
For Semaglutide, nausea and vomiting remain strong, expected signals. However, newer signals include NAION (an eye-related condition) which was under EMA review as of January 2025. There are also emerging signals for pulmonary aspiration (breathing foreign material into the lungs) during anesthesia due to delayed gastric emptying.
What is happening with BPC-157 and KPV?
Both BPC-157 and KPV have been through the regulatory wringer lately.
- BPC-157: The FDA has identified concerns including immunogenicity (the body having an immune response to the peptide) and a lack of human safety data. It was reviewed by the Pharmacy Compounding Advisory Committee in July 2026.
- KPV: Similar to its peers, KPV was reviewed in July 2026. The FDA noted there is limited information on how humans react to it and lingering safety uncertainty.
Other regulatory red flags
Several other compounds are currently in Category 2, which means the FDA has identified significant safety risks or a lack of evidence for them.
- GHRP-2 and GHRP-6 are in Category 2 due to immunogenicity concerns.
- Melanotan II is listed due to multiple serious adverse events and has safety warnings from both the FDA and TGA.
- LL-37 and PEG-MGF were also placed in Category 2 in September 2023 due to safety concerns.
How to navigate this safely
Scientists are still working on these — turns out the human body is complicated. Who knew?
This is a great one to bring up with your doctor. You can find peptide-experienced physicians in our Find a Doctor directory. If you are looking for a professional to guide you, knowing how to find a peptide prescriber is the best first step.
This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.
Referenced Peptides
This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.